
Panbela Therapeutics: A biopharmaceutical firm specializing in pancreatic cancer treatments.
Founded with a mission to develop innovative treatments for pancreatic cancer, Panbela Therapeutics is a biopharmaceutical company dedicated to improving patient outcomes in oncology. The company's core vision is to advance the science of cancer treatment through rigorous research and development. Panbela's primary product offerings include therapeutics specifically designed for pancreatic cancer, with a focus on novel drug combinations that enhance efficacy and safety. Their market focus is on addressing the unmet medical needs of cancer patients globally.
Notable achievements for Panbela Therapeutics include the issuance of new patents in the US and Canada for a fixed-dose combination of eflornithine and sulindac, which underscores their commitment to innovation. The company has also garnered attention through presentations at prominent medical conferences such as Digestive Disease Week (DDW). With a strong foundation of scientific expertise and strategic partnerships, Panbela continues to make significant strides in the biopharmaceutical industry, aiming to transform the landscape of cancer treatment and improve patient survival rates.

Panacela Labs
panacelalabs.com

Panacea Pharmaceuticals

PanTher Therapeutics
panthertx.com

PNP Therapeutics

Traws Pharma

Palm Therapeutics

Puma Biotechnology

Saladax Biomedical

Pelican Therapeutics

PTC Therapeutics
ptcbio.com

Ascenta Therapeutics

G1 Therapeutics
g1therapeutics.com

PanTheryx
pantheryx.com

Pinnacle Biologics

PellePharm
pellepharm.com
Companies similar to Panbela Therapeutics include Panacela Labs, Panacea Pharmaceuticals, PanTher Therapeutics and PNP Therapeutics.
Panbela Therapeutics was founded in 2011.
Panbela Therapeutics' headquarters is located in Waconia, MN, US.
Panbela Therapeutics' most recent funding round was for $9M (USD) in January 2024.
As of Jan 29, 2024, Panbela Therapeutics has raised a total of $64.4M (USD).
Panbela Therapeutics has 5 employees as of Feb 6, 2024.